Precision Oncology in Pancreatic Cancer: Experiences and Challenges of the CCCMunichLMU Molecular Tumor Board-Reference-Cited by-同舟云学术

Precision Oncology in Pancreatic Cancer: Experiences and Challenges of the CCCMunichLMU Molecular Tumor Board

Published:2023-02-28 Issue:2 Volume:18 Page:257-267
ISSN:1776-2596
Container-title:Targeted Oncology
language:en
Short-container-title:Targ Oncol

Author:

Dorman Klara,Zhang Danmei,Heinrich Kathrin,Reeh Laurens,Weiss Lena,Haas Michael,Beyer Georg,Rössler Daniel,Goni Elisabetta,Renz Bernhard W.,D’Haese Jan G.,Kunz Wolfgang G.,Seidensticker Max,Corradini Stefanie,Niyazi Maximilian,Ormanns Steffen,Kumbrink Jörg,Jung Andreas,Klauschen Frederick,Werner Jens,Mayerle Julia,von Bergwelt-Baildon Michael,Boeck Stefan,Heinemann Volker,Westphalen C. Benedikt^ORCID

Funder

Universitätsklinik München

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical),Cancer Research,Oncology

Link

https://link.springer.com/content/pdf/10.1007/s11523-023-00950-0.pdf

Reference31 articles.

1. Mosele F, Remon J, Mateo J, Westphalen CB, Barlesi F, Lolkema MP, et al. Recommendations for the use of next-generation sequencing (NGS) for patients with metastatic cancers: a report from the ESMO Precision Medicine Working Group. Ann Oncol. 2020;31(11):1491–505. https://doi.org/10.1016/j.annonc.2020.07.014.

2. Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer statistics, 2021. CA Cancer J Clin. 2021;71(1):7–33. https://doi.org/10.3322/caac.21654.

3. Dorman K, Heinemann V, Kobold S, von Bergwelt-Baildon M, Boeck S. Novel systemic treatment approaches for metastatic pancreatic cancer. Expert Opin Investig Drugs. 2022;31(3):249–62. https://doi.org/10.1080/13543784.2022.2037552.